v-src Induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells

International Journal of Cancer

Volumn 80, Issue 5, 1999, Pages 731-737

  Masumotu, Naoko ^a   Nakano, Shuji ^a   Fujishima, Hiromitsu ^a   Kohno, Kimitoshi ^b   Niho, Yoshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG DNA BINDING; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; ONCOGENE SRC; PRIORITY JOURNAL; TREATMENT FAILURE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANDROSTADIENES; BENZOQUINONES; CELL SURVIVAL; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GALLBLADDER NEOPLASMS; GENES, SRC; HUMANS; LACTAMS, MACROCYCLIC; LACTONES; MACROLIDES; ONCOGENE PROTEIN PP60(V-SRC); PROTEIN-TYROSINE KINASES; QUINONES; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032924293     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H     Document Type: Article

References (41)

1. ALI-OSMAN, F., BERGER, M.S., RAJAGOPAL, S., SPENCE, A. and LIVINGSTON, R.B., Topoisomerase-II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res., 53, 5663-5668 (1993).
2. c-src protein kinase activity in human colon carcinoma. Proc. nat. Acad. Sci. (Wash.), 84, 2251-2255 (1987).
3. BOS, J.L., Ras oncogenes in human cancer. Cancer Res., 49, 4682-4689 (1989).
4. BROWN, M.T. and COOPER, J.A., Regulation, substrates and functions of src. Biochim. Biophys. Acta. 1287, 121-149 (1996).
5. CAMPBELL, G., YU, C., JOVE, R. and CARTER-SU, C., Constitutive activation of JAK1 in src-transformed cells. J. biol. Chem., 227, 2591-2594 (1997).
6. c-src activation in human colon carcinoma. J. clin. Invest., 83, 2025-2033 (1989).
7. CRUMPLIN, G.C., The involvement of DNA topoisomerases in DNA repair and mutagenesis. Carcinogenesis, 2, 157-160 (1981).
8. ESAKI, T., NAKANO, S., TATSUMOTO, T., KUROKI-MIGITA, M., MITSUGI, K., NAKAMURA, M. and NIHO, Y., Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma. Cancer Res., 52, 6501-6506 (1992).
9. FUJISHIMA, H., NAKANO, S., TATSUMOTO, T., MASUMOTO, N. and NIHO, Y., Interferon-α and -γ inhibit the growth and neoplastic potential of v-src-transformed human epithelial cells by reducing src tyrosine kinase activity. Int. J. Cancer, 76, 423-239 (1998).
10. FUKAZAWA, H., KI, P.M., YAMAMOTO, C., MURAKAMI, Y., MIZUNO, S. and UEHARA, Y., Specific inhibition of cytoplasmic protein kinases by herbimycin A in vitro. Biochem. Pharmacol., 42, 1661-1671 (1991).
11. GEDIK, C.M. and COLLINS, A.R., Comparison of effects of fostriecin, novo-biocin and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells. Nucleic Acids Res., 18, 1007-1014 (1990).
12. HAMILTON, T.C., WINKER, M.A., LOUIE, K.G., BATIST, G., BEHRENS, B.C., TSURUO, T. GROTZINGER, K.R., MCKOY, W.M., YOUNG, R.C. and OZOLS, R.F., Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol., 34, 2583-2586 (1985).
13. HENNIPMAN, A., VAN OIRSCOT, B.A., SMITS, J., RIJKSEN, G. and STAAL, G.E.J., Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res., 49, 516-521 (1987).
14. HIDAKA, H., INAGAKI, M., KAWAMOTO, S. and SASAKI, Y., Isoquinoline-sulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase C. Biochemistry, 23, 5036-5041 (1984).
15. ISONISHI, S., HOM, D.K., THIEBAUT, F.B., MANN, S.C., ANDREWS, P.A., BASU, A., LAZO, J.S., EASTMAN, A. and HOWELL, S.B., Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res., 51, 5903-5909 (1991).
16. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50, 5184-5191 (1990).
17. v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res., 52, 2926-2930 (1992).
18. LEVY, E., BAROCHE, C., BARRET, J.M., ALAPETITE, C., SALLES, B., AVERBECK, D. and MOUSTACCHI, E., Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis, 15, 845-850 (1994).
19. MASUMOTO, N., NAKANO, S., FUJISHIMA, H., TATSUMOTO, T. and NIHO, Y., Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells. Int. J. Cancer, 62, 70-75 (1995).
20. MATSUO, K., KOHNO, K., SATO, S., UCHIUMI, T., TANIMURA, H., YAMADA, Y. and KUWANO, M., Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Res., 53, 1085-1090 (1993).
21. MURAKAMI, Y., NAKANO, S., NIHO, Y., HAMASAKI, N. and IZUHARA, K., Consutitutive activation of jak-2 and tyk-2 in a v-src-transformed human gallbladder adenocarcinoma cell line. J. cell. Physiol., 175, 220-228 (1998).
22. NAKAMO, S., TATSUMOTO, T., ESAKI, T., NAKAMURA, M., BABA, E., KIMURA, A., OHSHIMA, K. and NIHO, Y., Characterization of a newly established human gallbladder-carcinoma cell line. In Vitro cell. dev. Biol., 30A, 729-732 (1994).
23. OKABE, T.Y., OKABE, H.Y., KASHIMA, Y. and DOI, R., Effects of oncogenes on the resistance to cis-diamminedichloroplatinum (II) and metallothionein gene expression. Toxicol. Pharmacol., 133, 233-238 (1995).
24. OTTEFHOFF-KALFF, A.E., RIJKSEN, G., VAN BEURDEN, E.A.C.M., HENNIPMAN, A., MICHELS, A.A. and STAAL, G.E.J., Characterization of protein tyrosine kinases from human breast cancer: involvement of c-src oncogene product. Cancer Res., 52, 4773-4778 (1992).
25. PEREZ, R.P., HAMAGUCHI, K., TRACY, P.A., HANDEL, L.M., HAMILTON, T.C. and GODWIN, A.K., Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. Cancer Res., 53, 3771-3775 (1993).
26. PETERS, G.J., WETS, M., KEEPERS, Y.P.A.M., OSKAM, R., VAN ARK-OTTE, NOORDHUIS, P., SMID, K. and PINEDO, H.M., Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer, 54, 450-455 (1993).
27. SCHNEIDER, P.M., HUNG, M.C., CHIOCCA, S.M., MANNING, J., ZHAO, X., FANG, K. and ROTH, J.A., Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49, 4968-4971 (1989).
28. SKLER, M.D., Increased resistance to cis-diamminedichloroplatinum (II) in NIH-3T3 cells transformed by ras oncogenes. Cancer Res., 48, 793-797 (1988).
29. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.G., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J., ULLRICH, A. and PRESS, M.F., Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
30. TAKANO, H., KOHNO, K., MATSUO, K., MATSUDA, T. and KUWANO, M., DNA topoisomerase-targeting antitumor agents and drug resistance. Anticancer Drugs, 3, 323-330 (1992).
31. c-src in progressive stages of human colorectal cancer. J. clin. Invest., 91, 53-60 (1993).
32. TATSUKA, M., OTA, T., YAMAGISHI, N., KASHIHARA, Y., WADA, M., MATSUDA, N., MITSUI, H., SEIKI, M. and ODASHIMA, S., Different metastatic potentials of ras- and src-transformed BALB/c 3T3 A31 variant cells. Mol. Carcinogenesis, 15, 300-318 (1996).
33. TATSUMOTO, T., NAKANO, S., SHIMIZU, K., ONO, M., ESAKI, T., OHSHIMA, K. and NIHO, Y., Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene. Int. J. Cancer, 61, 206-213 (1995).
34. TIETZE, F., Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal. Biochem., 27, 502-522 (1969).
35. TOFFOLI, G., VIEL, A., TUMIOTTO, L., BUTTAZI, P., BISCONTIN, G. and BOIOCCHI, M., Sensitivity pattern of normal and Ha-ras transformed NIH3T3 fibroblasts to antineoplastic drugs. Tumori, 75, 423-428 (1989).
36. neu expressing non-small cell lung cancer cells. Cancer Res., 56, 1068-1074 (1996).
37. neu in the HER-2/neu transfected human lung cancer cells. J. nat. Cancer Inst., 87, 682-684 (1995).
38. YANG, J.L., YU, Y., MARKOVIC, B., RUSSELL, P.J. and CROWE, P.J., Overexpression of c-erbB-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer. Anticancer Res., 17, 1023-1026 (1997).
39. YANO, H., NAKANISHI, S., KIMURA, K., HANAI, N., SAITOH, Y., FUKUI, Y., NONOMURA, Y. and MATSUDA, Y., Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J. biol. Chem., 268, 25846-25856 (1993).
40. YU, D., WANG, S.S., DULSKI, K.M., TSAI, C.M., NICOLSON, G.L. and HUNG, M.C., c-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated proteins. Cancer Res., 54, 3260-3266 (1994).
41. ZHANG, L. and HUNG, M.C., Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12, 571-576 (1996).